A phase I study of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy in combination with daratumumab in relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Juckett, M.; Mailankody, S.; Eghtedar, A.; Bickers, C.; Zong, X.; Wong, L.; Ly, T.; Byon, J.; Cooley, S.; Valamehr, B.; Chu, Y. W.; Vij, R. |
| Abstract Title: | A phase I study of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy in combination with daratumumab in relapsed/refractory multiple myeloma |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 10327 |
| End Page: | 10328 |
| Language: | English |
| ACCESSION: | WOS:000893230303151 |
| DOI: | 10.1182/blood-2022-166728 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
